Gilead's Big Setback
Behind the complete response letter (CRL) Gilead Sciences and Galapagos just received for an important compound they were developing together.
FDA hands Gilead a stunning rejection for blockbuster RA candidate filgotinib, dealing CEO O’Day a major setback
In a surprise twist, the FDA has rejected Gilead’s marketing application for filgotinib, dealing a body blow to Daniel O’Day’s hopes for a rapid improvement in the big biotech’s drug portfolio with a blockbuster addition. Late on Tuesday, Gilead $GILD put out word that the agency had turned thumbs-down on